Transforming our organisation to meet global expansion

Global Director – Icon Cancer Centre – Ross Koscharsky
Ross Koscharsky has been Chief Financial Officer (CFO) since the formation of Icon Group, playing a key role in Icon’s growth. Having led each of our acquisitions, Ross is adept at leading change and successfully driving significant growth and integration. His unparalleled knowledge of Icon Group’s global operations, deep executive and doctor relationships, and proven leadership skills mean Ross is perfectly placed to lead the next stage of Icon’s cancer care and research portfolio across Australia, New Zealand, Singapore, Hong Kong, and Mainland China.

Current cancer division leaders – Paul Fenton (CEO Icon Cancer Centre AU/NZ), Sophie Mepham (Group Executive Research Global), Chelsea Ren (CEO Icon Cancer Centre China) and Serena Wee (CEO Icon Cancer Centre ASEAN and Hong Kong) will report to Ross.  

Ross officially steps into this role following the appointment of the Group’s new Chief Financial Officer. 

“Ross’ strategic and operational knowledge of Icon Group is immense and there’s no doubt he has the credentials to direct our cancer care services on a global scale while upholding our commitment to clinical excellence and patient care.” said Icon Group Chief Executive Officer (CEO) Mark Middleton.

Global Director – Pharmacy and Compounding – David Slade
As founder of Icon’s compounding division, David Slade brings unmatched clinical expertise, strategic insight, and entrepreneurial vision to this new strategic role. David has been responsible for significant growth across our pharmacy and compounding division including Icon’s first international TGA licensed facility in New Zealand and the opening of Australia’s first research stability lab.  

“David’s reputation for excellence in healthcare is second to none and his vision for growth will confidently allow us to enter new markets and the next phase of expansion. His evolution within Icon’s executive leadership team is a natural progression and the ideal appointment for Icon to succeed.” said CEO Mark Middleton.

Chief Medical Officer – Dr Ian Irving 

Ian’s role as Global Medical Director will evolve to Chief Medical Officer which will see a continued focus on guiding clinical governance and further developing our doctor network globally. Ian brings a wealth of clinical and operational experience to this role and his in-depth understanding of Icon’s impressive doctor network will strengthen the group’s commitment of doctor-led, patient-centred care. Ian will continue to work with our broader clinical leadership group.

Chief of Staff and Chief Transformation Officer – Tracey Fyvie

Throughout her time with Icon, Tracey has driven a strong growth agenda across our development and strategic investment portfolio, while maturing Icon’s global clinical practice functions. As Chief of Staff, Tracey will partner with the Group CEO to oversee Icon Group’s operations, lead and embed governance and increase performance, alongside our Executive team. As Chief Transformation Officer, Tracey will lead us to successfully deliver the FPP and its transformational initiatives. 

Chief Marketing & Communication Officer – Jenny Hansen

Jenny’s current role as Group Executive – Brand and Communications evolves to Chief Marketing & Communication Officer. This role will have a continued focus on strategic communication, marketing, and customer experience. Jenny’s extensive knowledge of healthcare and Icon will drive forward new initiatives in the patient experience portfolio and improve our connection with Icon’s stakeholders and wider community.